Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.77 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.77 |
| ▸ | HTR2C | P28335 | 7/20 | 0.57 |
| ▸ | HTR2B | P41595 | 6/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.57 |
| ▸ | MELK | Q14680 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.48 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.48 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.48 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.48 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.48 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.48 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.48 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.48 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.48 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21753269 | 0.98 | PNMT (0.74) | PNMTASIC3HTR2CHTR2BHTR2A | |
| SCHEMBL12895998 | 0.92 | PNMT (0.67) | PNMTASIC3HTR2CHTR2BHTR2A | |
| SCHEMBL29473102 | 0.87 | PNMT (1.00) | PNMTASIC3HTR2CHTR2BHTR2A | |
| SCHEMBL505055 | 0.87 | ASIC3 (1.00) | PNMTASIC3HTR2CHTR2BHTR2A | |
| SCHEMBL552932 | 0.87 | PNMT (1.00) | PNMTASIC3HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL1017313 | 0.85 | ASIC3 (0.96) | PNMTASIC3HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL1266299 | 0.85 | PNMT (0.96) | PNMTASIC3HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL29528420 | 0.85 | PNMT (0.96) | PNMTASIC3HTR2CHTR2BHTR2A | |
| SCHEMBL13594 | 0.83 | — | — | |
| Ammonia Solution, Strong SCHEMBL8701960 | 0.80 | PNMT (0.56) | PNMTASIC3PARP10PARP11PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547246-A2 | COMPOUNDS AS INHIBITORS OF AXL | Arcus Biosciences, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12195482-B1 | Compounds as inhibitors of AXL | ARCUS BIOSCIENCES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240425526-A1 | COMPOUNDS AS INHIBITORS OF AXL | ARCUS BIOSCIENCES, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| EP-3601229-B1 | TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS | CALDAN THERAPEUTICS LTD (GB) | 2024-11-06 | — | — | EP | disclosed |
| CN-115594669-B | Parallel ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-11-05 | — | — | CN | disclosed |
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024006726-A2 | COMPOUNDS AS INHIBITORS OF AXL | ARCUS BIOSCIENCES, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230416277-A1 | COMPOUNDS AS INHIBITORS OF AXL | ARCUS BIOSCIENCES, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-7304050-B2 | Antibacterial agents | PFIZER INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304050-B2 | Antibacterial agents | PFIZER INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| EP-1594494-A1 | OXAZOLIDINONE DERIVATIVES N-SUBSTITUTED BY A BICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040224939-A1 | Antibacterial agents | CHUPAK LOUIS S (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004069244-A1 | OXAZOLIDINONE DERIVATIVES N-SUBSTITUTED BY A BICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-19 | — | — | WO | disclosed |
| EP-1011679-B1 | USE OF 8-NITRO-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SLEEP DISORDERS | ADDEX PHARMACEUTICALS SA (CH) | 2003-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224939-A1 | Antibacterial agents | MRPL21, RPN2, FBL | PNMT 3757/4885ASIC3 4530/4885HTR2C 4790/4885 |
| US-12195482-B1 | Compounds as inhibitors of AXL | AXL, FLT3, BTK | PNMT 3497/4885ASIC3 2252/4885HTR2C 4165/4885 |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | FGF1, FGF2, FGFR1 | PNMT 4852/4885ASIC3 544/4885HTR2C 1517/4885 |
| US-20240226115-A1 | AXL INHIBITOR COMPOUNDS | AXL, BTK, MERTK | PNMT 3997/4885ASIC3 2819/4885HTR2C 4367/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | PNMT 998/4885ASIC3 4164/4885HTR2C 2813/4885 |
| US-20240425526-A1 | COMPOUNDS AS INHIBITORS OF AXL | AXL, FLT3, BTK | PNMT 3497/4885ASIC3 2252/4885HTR2C 4165/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | PNMT 1190/4885ASIC3 4447/4885HTR2C 3311/4885 |
| US-20230416277-A1 | COMPOUNDS AS INHIBITORS OF AXL | AXL, FLT3, BTK | PNMT 3497/4885ASIC3 2252/4885HTR2C 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.